Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

NOVOPHARM RANITIDINE FORM 1 CONTAINS DETECTABLE AMOUNTS FORM 2, GLAXO CONTENDS AT TRIAL; CLAIMS NOVOPHARM STOLE MANUFACTURING TRADE SECRETS

  • News

Executive Summary

Novopharm's generic version of Glaxo Wellcome's Zantac contains detectable amounts of Form 2 ranitidine hydrochloride, Glaxo contended in opening statements April 16 in Elizabeth City, N.C. federal court in a suit Glaxo filed against Novopharm for its filing of an ANDA for Form 1 ranitidine.

You may also be interested in...



Sanofi Plavix Patent On Polymorphic Form Covers Currently Marketed Product

Sanofi-Synthelabo's latest patent for its antithrombotic Plavix covers the polymorphic form of clopidogrel that is currently marketed in the U.S., the company said

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Table

View full table

Tags:
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS028036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By